Key Takeaway
The Medicare GLP-1 Bridge program begins July 1, 2026, giving eligible Part D beneficiaries early access to Wegovy, Foundayo, and Zepbound KwikPen before full Part D weight-loss coverage arrives January 1, 2027. Zepbound also gets a $50/month cap starting April 2026.
For the first time in Medicare's history, weight-loss GLP-1 medications are about to move from cash-pay territory to covered benefit. The Centers for Medicare and Medicaid Services (CMS) built a phased rollout so seniors dont wait another year for help. If youre on Medicare and youve been priced out of Wegovy or Zepbound, the next nine months change everything.
Here's what the Bridge program does, who it covers, and the moves you should make before July 1.
What is the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge is a transitional coverage pathway running from July 1, 2026 through December 31, 2026. It lets eligible Part D beneficiaries fill prescriptions for approved weight-loss GLP-1s at reduced cost-sharing while CMS finalizes formularies for full Part D coverage that starts January 1, 2027.
Until now, Medicare by law couldnt cover drugs prescribed solely for weight loss. That restriction dates to the 2003 Medicare Modernization Act. The Inflation Reduction Act, paired with 2025 CMS rulemaking on obesity as a chronic disease, created the legal pathway. The Bridge exists because CMS didnt want to make 65 million beneficiaries wait six extra months while plan sponsors updated formularies.
Think of it as a pilot with teeth. Plans that opt in get federal reimbursement for covered fills, and beneficiaries get a preview of what 2027 benefits will look like.
Who qualifies for coverage?
You qualify for the Bridge if you have active Medicare Part D coverage, a BMI of 30 or higher (or 27+ with at least one weight-related comorbidity like type 2 diabetes, hypertension, or sleep apnea), and a prescription from a Medicare-enrolled prescriber. Plan sponsors will layer prior authorization and step therapy on top of these federal minimums.
The comorbidity list matters. About 71% of Medicare beneficiaries over 65 have at least one qualifying condition, according to CMS chronic-condition data from 2025. That pulls tens of millions of seniors into eligibility even if theyre below the BMI 30 threshold.
Dual-eligible beneficiaries (Medicare plus Medicaid) get an additional pathway through the BALANCE model, which activates in Medicaid opt-in states starting May 2026. BALANCE coordinates coverage so duals dont fall through the cracks between state and federal formularies. If you live in a non-expansion state, coverage flows only through Part D.
Medicare Advantage enrollees are included. Your MA-PD plan must cover at least one GLP-1 from the CMS-approved list, though the specific drug and tier placement vary by plan.
Which GLP-1 medications are covered?
The Bridge covers three medications: Wegovy (semaglutide injectable), Foundayo (orforglipron, the oral once-daily pill from Eli Lilly), and Zepbound KwikPen (tirzepatide in a multi-dose pen device). Ozempic and Mounjaro remain covered only for type 2 diabetes, since theyre not FDA-approved for weight loss.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Foundayo is the wild card here. Its the first oral GLP-1 agonist approved for chronic weight management, cleared by the FDA in late 2025 after the ATTAIN-1 and ATTAIN-2 trials showed 11.2% average weight loss at 72 weeks. For seniors who cant tolerate injections or have dexterity issues, a pill changes the calculus. FormBlends covers orforglipron in detail in our oral GLP-1 guide.
Zepbound KwikPen, approved in early 2026, replaces the single-use auto-injectors with a reusable pen that holds four doses. CMS negotiated the KwikPen specifically because it reduced per-dose manufacturing cost and let Lilly accept the $50/month price cap.
Not covered under the Bridge: compounded semaglutide or tirzepatide, Saxenda (liraglutide), and any off-label GLP-1 use. If your current prescription is compounded, youll need to transition to brand before July 1 to use Bridge benefits.
How does the $50/mo Zepbound cap work?
Starting April 1, 2026, Eli Lilly caps out-of-pocket cost for Zepbound at $50 per month for Medicare Part D beneficiaries, whether or not the Bridge program has activated yet. The cap applies at the pharmacy counter through a manufacturer copay assistance program that works alongside Part D benefits.
Before this cap, Medicare patients paid $900 to $1,600 per month out of pocket for Zepbound since Part D excluded weight-loss coverage. The cap is Lilly's response to competitive pressure from Novo Nordisks Wegovy pricing and the Inflation Reduction Act negotiation framework. Its not charity, its market positioning ahead of 2027 formulary placement.
The mechanics: your pharmacy runs your Part D claim first, then the Lilly assistance program covers remaining out-of-pocket up to the $50 cap. You show your Medicare card and the Zepbound savings card (available at zepbound.com or through your prescriber). No income cap applies on the Bridge-era version of the program.
Wegovy hasnt matched the $50 number yet. Novo Nordisk currently offers a $199/month cash pay program for Medicare patients ineligible for coverage, with formal cap announcements expected before July. Compare current pricing in our Ozempic and GLP-1 cost guide for 2026.
What happens between July 2026 and January 2027?
The Bridge period is a six-month preview window. Part D plans that opt in start covering eligible GLP-1 fills July 1, with standard tier cost-sharing (typically Tier 3 or Tier 4 preferred brand). Plans not opting in direct beneficiaries to manufacturer assistance programs and existing cash-pay channels.
CMS estimates 78% of standalone Part D plans and 85% of MA-PD plans will opt in, based on preliminary bid data submitted in June 2025. That leaves a coverage gap for beneficiaries in non-participating plans, mostly regional or low-premium plans that couldnt absorb the cost without premium increases.
Here's the timeline you need to track:
| Date | Milestone |
|---|---|
| April 1, 2026 | Zepbound $50/month cap for Medicare beneficiaries takes effect |
| May 1, 2026 | BALANCE model launches in Medicaid opt-in states for dual-eligibles |
| July 1, 2026 | Medicare GLP-1 Bridge program begins for eligible Part D beneficiaries |
| October 15, 2026 | Medicare Open Enrollment starts; 2027 plan formularies published |
| December 31, 2026 | Bridge program ends |
| January 1, 2027 | Full Medicare Part D GLP-1 weight-loss coverage begins across all plans |
Open Enrollment in October is when things get strategic. Youll see 2027 formularies published, and if your current plan excludes GLP-1s or tiers them poorly, you can switch during the October 15 to December 7 window.
What should Medicare patients do right now?
Start with three moves before July. First, get a documented BMI and comorbidity record from your primary care provider. Bridge eligibility hinges on chart documentation, not self-report. If your last weight check was more than six months ago, schedule one. Second, pull your current Part D plan's preliminary 2026 formulary update, which most plans publish mid-April. Confirm whether your plan is opting into the Bridge.
Third, decide your drug preference now. If you want Wegovy, youre on a weekly injection pathway. If Zepbound KwikPen fits your budget better with the $50 cap, youll need a prescriber willing to write it. If Foundayo appeals because its oral, confirm your plan covers it, since some plans initially tiered orforglipron higher than injectables.
For the 81% of large employer plans that still dont cover GLP-1s for weight loss (based on Mercer 2026 data), Medicare beneficiaries coming off employer plans at 65 are actually better positioned under the new Bridge than their still-working peers. Thats a weird inversion of how coverage usually works.
If you dont qualify for the Bridge or your plan opts out, telehealth cash-pay channels remain available. FormBlends compares covered and uncovered pathways in our 2026 State of GLP-1 Telehealth report, and our no-insurance weight-loss guide walks through options when Medicare or employer coverage isnt available.
Ready to talk to a licensed prescriber about GLP-1 options? Start your consultation or browse the FormBlends provider directory to find clinicians who work with Medicare patients.
Frequently asked questions
Will Original Medicare (Parts A and B) cover GLP-1s for weight loss?
No. Weight-loss GLP-1 coverage flows exclusively through Part D and Medicare Advantage Prescription Drug (MA-PD) plans. Part B still doesnt cover outpatient prescription drugs for obesity. If you only have Parts A and B, youll need to enroll in a standalone Part D plan during Open Enrollment to access Bridge benefits.
What if I'm already on Ozempic or Mounjaro for diabetes?
Keep your current prescription. Ozempic and Mounjaro remain covered under Part D for type 2 diabetes and arent part of the Bridge program. The Bridge specifically adds coverage for weight-loss indications. If you want to switch to a weight-loss-indicated drug like Wegovy or Zepbound, talk to your prescriber about whether that makes clinical sense.
Do I need to fail another weight-loss medication first (step therapy)?
Plan sponsors can require step therapy, and most will. The typical step-therapy sequence is documented lifestyle intervention for at least six months, followed by either phentermine or a non-GLP-1 obesity medication, before approving a GLP-1. Medical exceptions apply if step therapy is contraindicated for your specific conditions.
How much will I actually pay out of pocket?
It depends on drug and plan tier. Zepbound is capped at $50/month through the Lilly program. Wegovy cost-sharing varies by plan, typically $75 to $150/month at Tier 3. Foundayo pricing is still being finalized, with estimates in the $90 to $130/month range at standard Tier 3 placement. The Part D out-of-pocket maximum is $2,000 in 2026, which caps total annual drug spending.
Can I use the Bridge if Im in a Medicare Advantage plan?
Yes, if your MA-PD plan opts in. Most major MA-PD carriers (Humana, UnitedHealthcare, Aetna, Kaiser, Blue Cross plans) confirmed opt-in participation in their 2026 bid filings. Regional MA plans are mixed. Check your plan's 2026 Evidence of Coverage or call member services to confirm Bridge participation before July 1.
What happens to my coverage on January 1, 2027?
Full Part D GLP-1 coverage takes over. Every Part D and MA-PD plan must cover at least one GLP-1 from each approved indication class, with standard Part D cost-sharing rules. The Bridge's special copay assistance arrangements may continue or transition to standard tiered benefits depending on your plan's 2027 formulary decisions.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your healthcare provider before starting any medication. Individual results vary. FormBlends is a licensed telehealth platform; nothing here replaces a personal clinical evaluation.
Last reviewed: 2026-04-16